RE: Full Year Results27 Apr 2023 10:46
Prior to Covid, and going back some years now when RM was doing the rounds presenting at various investor meets, he always suggested that the aim was to ultimately sell out...numbers like £1bn for a P2 drug, £8bn for a phase 3 etc. (link below to such a presentation, 13mins in, slide 14)
https://www.youtube.com/watch?v=BzK7lCjN6Jw
At the AGM, chatting to RM and Bruce Campbell, they said it was about not panicking and making sure investors get what SNG001 is really worth. I don't see Synairgen taking the drug all the way to the end of another P3... rather, I reckon they are trying to make sure that it has the maximum chance of success if/when it does get on a P3, that will then make it very attractive for a BP to come in and offer good money.
The SP might be down today but I see support at this level because the financials weren't bad and there is a plan in place, albeit it's going to take a while. But of course there is also the possibility that we do get on STRIVE or another PT, as mentioned by them this morning - "Synairgen has been and remains in contact with the relevant platform trial investigators and will continue to evaluate options should they arise"
My big concern had been that PI's would get shafted somehow. Today has calmed those concerns somewhat. Questions that remain:
- What is going on with Polygon, are they insiders?
- What was the Medical Affairs Director job posting all about?
- What are those expensive senior hires doing?
The AGM can't come fast enough. They know they'll still be massive pressure on them, so have they held some good news back to drop in just before then?